Equities

Atara Biotherapeutics Inc

Atara Biotherapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)14.26
  • Today's Change2.59 / 22.19%
  • Shares traded303.89k
  • 1 Year change+121.86%
  • Beta0.5238
Data delayed at least 15 minutes, as of Nov 13 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments52243371
Total Receivables, Net34400.99
Total Inventory9.711.59--
Prepaid expenses----12
Other current assets, total6.33100.19
Total current assets102295385
Property, plant & equipment, net597480
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets4.847.022.37
Total assets166376468
LIABILITIES
Accounts payable3.686.8717
Accrued expenses606347
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.920.830.17
Other current liabilities, total788.0041
Total current liabilities14279106
Total long term debt35340
Total debt36350.17
Deferred income tax------
Minority interest------
Other liabilities, total8813783
Total liabilities265250189
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital1,8701,8221,745
Retained earnings (accumulated deficit)(1969)(1693)(1465)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.2)(2.07)(0.37)
Total equity(99)127280
Total liabilities & shareholders' equity166376468
Total common shares outstanding4.263.843.67
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.